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Abstract
Epstein-Barr virus (EBV) infects the vast majority of  humans and resides latently in B-cells. 
This virus carries genes that can induce and sustain mature B cell growth. EBV is associated 
with a wide range of  B-cell lymphomas including Burkitt lymphoma and non Hodgkin 
lymphoma (NHL) in human immunodeficiency virus 1 (HIV-1) infected patients. Latent EBV 
infection in B lymphocytes is a risk factor for B-cell lymphomas in conditions of  combined 
antigen stimulation and immunosuppression as with Burkitts lymphoma in malaria endemic 
African regions and non Hodgkin lymphoma in HIV-1 infected patients. In the era of  modern 
combination antiretroviral therapy (cART) there has been an impressive reduction of  Acquired 
Immunodeficiency syndrome (AIDS)-related opportunistic infections and lymphomas, 
although patients still suffer an increased risk for NHL. This work is based on EBV-DNA load 
measurement in blood as a tool to analyse EBV-host relationship in HIV-1 infection. 
In general HIV-1 infected individuals have a higher EBV-DNA load and symptomatic HIV-1 
infected even higher. Individual variables, immunological factors and treatments as cART affect 
this pattern. In one of  our studies we identified one group and one risk factor that influenced 
EBV-DNA load. HIV-1 infected individuals with a history of  a symptomatic primary infection 
in combination with induced immune stimulation by therapeutic vaccination/adjuvant showed 
an increased load. Without the vaccination/adjuvant stimuli this group did not show the same 
increase. HIV-1 infected patients with a history of  a symptomatic primary infection might 
therefore be at risk for developing NHL. Therapeutic vaccination/adjuvant increases the EBV-
DNA load and we regard this immunomodulation as a risk factor. Different pattern of  EBV-
host restoration by cART was seen in a long term follow of  patients with increased EBV-DNA 
load after vaccination. The EBV-host relation seems to be reconditioned by successful cART 
treatment, measured by the CD4+ cell count returning to normal levels, with some reservation 
for the functional restoration, together with remaining undetectable HIV-1 RNA. For 
individuals with unsuccessful cART treatment the distinct decrease of  EBV-DNA could not be 
seen. In a patient treated for EBV positive plasmablastic lymphoma we observed a sharp 
increase of  EBV-DNA load before clinical signs of  recurrence.
Measurement of  EBV-DNA load is valuable in monitoring disease progression in HIV-1 
infected patients. After cART treatment the dynamics of  EBV-DNA load reveal if  the antiviral 
treatment is suboptimal, even if  breakthroughs detected as HIV RNA peaks are missed. When 
an EBV positive tumour is treated successfully EBV-DNA monitoring can be of  importance to 
observe early signs of  relapse. Monitoring EBV-DNA load during therapeutic vaccination 
studies seems highly motivated. In conclusion EBV-DNA load analysis is a useful additional 
instrument to monitor different groups of  HIV-1 patients with increased risk for lymphoma 
development.
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